Get startedLog in
    Picture of GridAI Technologies logo

    GRDX — GridAI Technologies News Story

    0.000.00%
    us flag iconLast trade - 00:00
    TechnologySpeculativeMicro CapMomentum Trap
    All News

    Brief: First Wave BioPharma Says Initiation Of Phase 3 Trials For Latiglutenase Expected in H2 2024

    Picture of GridAI Technologies logoGridAI Technologies
    04/01/2024 12:28
    Jan 4 (Reuters) - First Wave BioPharma Inc  FWBI.O :
    * FIRST WAVE BIOPHARMA CHAIRMAN AND CEO ISSUES LETTER TO
SHAREHOLDERS HIGHLIGHTING RECENT ACCOMPLISHMENTS AND OUTLOOK FOR
2024
    * FIRST WAVE BIOPHARMA INC -  INITIATION OF PHASE 3 TRIALS
FOR
LATIGLUTENASE EXPECTED IN SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX9w8QJP 
Further company coverage:  FWBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on GridAI Technologies

    See all news